Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics

Continuous revision of the histologic and stage-wise classification of lung cancer by the World Health Organization (WHO) provides the foundation for therapeutic advances by promoting molecular targeted and immunotherapies and ensuring accurate diagnosis. Cancer epidemiologic data provide helpful in...

Descripción completa

Detalles Bibliográficos
Autores principales: Padinharayil, Hafiza, Varghese, Jinsu, John, Mithun Chacko, Rajanikant, Golgodu Krishnamurthy, Wilson, Cornelia M., Al-Yozbaki, Minnatallah, Renu, Kaviyarasi, Dewanjee, Saikat, Sanyal, Rupa, Dey, Abhijit, Mukherjee, Anirban Goutam, Wanjari, Uddesh Ramesh, Gopalakrishnan, Abilash Valsala, George, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308181/
https://www.ncbi.nlm.nih.gov/pubmed/37396553
http://dx.doi.org/10.1016/j.gendis.2022.07.023
_version_ 1785066192119005184
author Padinharayil, Hafiza
Varghese, Jinsu
John, Mithun Chacko
Rajanikant, Golgodu Krishnamurthy
Wilson, Cornelia M.
Al-Yozbaki, Minnatallah
Renu, Kaviyarasi
Dewanjee, Saikat
Sanyal, Rupa
Dey, Abhijit
Mukherjee, Anirban Goutam
Wanjari, Uddesh Ramesh
Gopalakrishnan, Abilash Valsala
George, Alex
author_facet Padinharayil, Hafiza
Varghese, Jinsu
John, Mithun Chacko
Rajanikant, Golgodu Krishnamurthy
Wilson, Cornelia M.
Al-Yozbaki, Minnatallah
Renu, Kaviyarasi
Dewanjee, Saikat
Sanyal, Rupa
Dey, Abhijit
Mukherjee, Anirban Goutam
Wanjari, Uddesh Ramesh
Gopalakrishnan, Abilash Valsala
George, Alex
author_sort Padinharayil, Hafiza
collection PubMed
description Continuous revision of the histologic and stage-wise classification of lung cancer by the World Health Organization (WHO) provides the foundation for therapeutic advances by promoting molecular targeted and immunotherapies and ensuring accurate diagnosis. Cancer epidemiologic data provide helpful information for cancer prevention, diagnosis, and management, supporting health-care interventions. Global cancer mortality projections from 2016 to 2060 show that cancer will overtake ischemic heart diseases (IHD) as the leading cause of death (18.9 million) immediately after 2030, surpassing non-small cell lung cancer (NSCLC), which accounts for 85 percent of lung cancers. The clinical stage at the diagnosis is the main prognostic factor in NSCLC therapies. Advanced early diagnostic methods are essential as the initial stages of cancer show reduced mortality compared to the advanced stages. Sophisticated approaches to proper histological classification and NSCLC management have improved clinical efficiency. Although immune checkpoint inhibitors (ICIs) and targeted molecular therapies have refined the therapeutic management of late-stage NSCLC, the specificity and sensitivity of cancer biomarkers should be improved by focusing on prospective studies, followed by their use as therapeutic tools. The liquid biopsy candidates such as circulating tumor cells (CTCs), circulating cell-free tumor DNA (cfDNA), tumor educated platelets (TEP), and extracellular vesicles (EVs) possess cancer-derived biomolecules and aid in tracing: driver mutations leading to cancer, acquired resistance caused by various generations of therapeutic agents, refractory disease, prognosis, and surveillance.
format Online
Article
Text
id pubmed-10308181
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Chongqing Medical University
record_format MEDLINE/PubMed
spelling pubmed-103081812023-06-30 Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics Padinharayil, Hafiza Varghese, Jinsu John, Mithun Chacko Rajanikant, Golgodu Krishnamurthy Wilson, Cornelia M. Al-Yozbaki, Minnatallah Renu, Kaviyarasi Dewanjee, Saikat Sanyal, Rupa Dey, Abhijit Mukherjee, Anirban Goutam Wanjari, Uddesh Ramesh Gopalakrishnan, Abilash Valsala George, Alex Genes Dis Review Article Continuous revision of the histologic and stage-wise classification of lung cancer by the World Health Organization (WHO) provides the foundation for therapeutic advances by promoting molecular targeted and immunotherapies and ensuring accurate diagnosis. Cancer epidemiologic data provide helpful information for cancer prevention, diagnosis, and management, supporting health-care interventions. Global cancer mortality projections from 2016 to 2060 show that cancer will overtake ischemic heart diseases (IHD) as the leading cause of death (18.9 million) immediately after 2030, surpassing non-small cell lung cancer (NSCLC), which accounts for 85 percent of lung cancers. The clinical stage at the diagnosis is the main prognostic factor in NSCLC therapies. Advanced early diagnostic methods are essential as the initial stages of cancer show reduced mortality compared to the advanced stages. Sophisticated approaches to proper histological classification and NSCLC management have improved clinical efficiency. Although immune checkpoint inhibitors (ICIs) and targeted molecular therapies have refined the therapeutic management of late-stage NSCLC, the specificity and sensitivity of cancer biomarkers should be improved by focusing on prospective studies, followed by their use as therapeutic tools. The liquid biopsy candidates such as circulating tumor cells (CTCs), circulating cell-free tumor DNA (cfDNA), tumor educated platelets (TEP), and extracellular vesicles (EVs) possess cancer-derived biomolecules and aid in tracing: driver mutations leading to cancer, acquired resistance caused by various generations of therapeutic agents, refractory disease, prognosis, and surveillance. Chongqing Medical University 2022-08-23 /pmc/articles/PMC10308181/ /pubmed/37396553 http://dx.doi.org/10.1016/j.gendis.2022.07.023 Text en © 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Padinharayil, Hafiza
Varghese, Jinsu
John, Mithun Chacko
Rajanikant, Golgodu Krishnamurthy
Wilson, Cornelia M.
Al-Yozbaki, Minnatallah
Renu, Kaviyarasi
Dewanjee, Saikat
Sanyal, Rupa
Dey, Abhijit
Mukherjee, Anirban Goutam
Wanjari, Uddesh Ramesh
Gopalakrishnan, Abilash Valsala
George, Alex
Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
title Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
title_full Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
title_fullStr Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
title_full_unstemmed Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
title_short Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
title_sort non-small cell lung carcinoma (nsclc): implications on molecular pathology and advances in early diagnostics and therapeutics
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308181/
https://www.ncbi.nlm.nih.gov/pubmed/37396553
http://dx.doi.org/10.1016/j.gendis.2022.07.023
work_keys_str_mv AT padinharayilhafiza nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics
AT varghesejinsu nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics
AT johnmithunchacko nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics
AT rajanikantgolgodukrishnamurthy nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics
AT wilsoncorneliam nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics
AT alyozbakiminnatallah nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics
AT renukaviyarasi nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics
AT dewanjeesaikat nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics
AT sanyalrupa nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics
AT deyabhijit nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics
AT mukherjeeanirbangoutam nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics
AT wanjariuddeshramesh nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics
AT gopalakrishnanabilashvalsala nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics
AT georgealex nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics